Early-Phase Oncology Research Expertise Catalyst Oncology is a specialty oncology CRO devoting time, energy, and capital to supporting biotechs Read Now
Comprehensive and Flexible Partnership to Support Rescue Study A biotech company new to clinical research with an asset early in its development lifecycle became a long-term partner with Catalyst Flex. For years, Catalyst has worked alongside to help achieve the client’s goals for a single asset for the first bladder cancer therapy on the horizon in the past 20 years. Read Now
Focused Monitoring Support for Rare Disease Study A small biotech needed functional support for a Phase III rare disease study. Although a contract
existed between the biotech and a clinical research organization (CRO), the study timelines and budget
had slipped. The biotech hired Catalyst Flex to reverse that trend and ultimately saved ~$1 million. Read Now
Helping to Bring Cancer Therapies to Patients Niche CRO with a difference Catalyst Oncology is a niche oncology CRO devoting time, energy, Read Now
Expanding Clinical Trial Diversity: A Catalyst Values Approach “Today, overall cancer clinical trial enrollment in the United States is 8% (6.3%‐7.0% at community Read Now
Helping to Bring Immunotherapies to Cancer Patients in Need Catalyst Oncology is a specialty oncology clinical research organization (CRO) devoting time, energy, and capital Read Now
Automation of Exploratory Report Generation Using R Shiny and R Markdown Exploratory data analysis (EDA) in clinical research involves analyzing and summarizing data to extract insights, Read Now
Highlights of ESMO 2023: The year of ADCs Insights from the annual oncology conference By Andrew Zupnick, PhD, Vice President of Oncology Drug Read Now
Catalyst Clinical Research Honored for Innovative Use of AI Catalyst Accepts Award for Our Support of Drug Development Recognition from Medidata for support of Read Now
Catalyst Clinical Research Named One of Fastest Growing Companies Catalyst Ranks in Top of Annual List For fourth consecutive year, CRO recognized for its Read Now